All news - Fagron

This is Fagron News & Media All news

Filter by year

All 2023 2022 2021 2020 2019 2018 2017

Filter by category

All News Personalized medicine ESG Studies FACOs

Choosing the Right Excipient for Optimal Dosage Form Performance in Immunocompromised Patients

A research recent featured in the Journal of AIDS and HIV Research showed the potential of Low-Dose Naltrexone (LDN) in stabilizing CD4 counts among untreated HIV+ individuals and amplifying CD4 count increments when used alongside antiretroviral therapy. This breakthrough offers promising prospects for advancing HIV management strategies. Compounding of LDN capsules In the realm of … Continued

Technologies that assist in compounding

Compounding pharmacies play a crucial role in the healthcare landscape, offering personalized medication solutions to the unique needs of individual patients. One key aspect that compounding pharmacies address is the concept of reproducibility, ensuring that each compounded medication is consistently and accurately reproduced. The Importance of Reproducibility Reproducibility in compounding pharmacies refers to the ability … Continued

Preventing corruption and bribery

We value transparency and good business ethics and corporate culture

Enhancing Psoriasis Treatment with Advanced Compounding Solutions

Psoriasis, a widespread autoimmune condition, impacts approximately 125 million individuals globally. A majority of psoriasis sufferers, around 80%, experience a milder form of the disease that can be effectively managed using topical treatments. These topical solutions serve various purposes, with different formulations suited for different aspects of the condition. Recent advancements in psoriasis research have … Continued

SyrSpend® SF PH4 NEO has a new brochure!

Fagron’s range of oral suspending vehicles, SyrSpend® SF, offers a solution for different patient groups by providing pharmaceutical stability, dosage consistency, and patient comfort with each preparation. The content was updated to provide you with a better understanding of this specific pediatric subgroup and how SyrSpend® SF PH4 NEO can facilitate their personalized treatment. One of the most important … Continued

Science-based carbon footprint targets – Part 2

The SBTi has approved Fagron’s near-term science-based emissions reduction target. In September 2022, we committed to set science-based emission reduction targets and have these validated by the Science Based Targets initiative (SBTi) to meet the goals of the Paris Agreement of limiting global warming to 1.5°C. As part of our commitment to the SBTi, we … Continued

Library: A repository for all Fagron-related scientific literature

Science is an integral part of Fagron’s identity and our approach to product development. As an organization, we are committed to remaining the leader in scientific production within the field of pharmaceutical compounding, by generating an unrivaled number of peer-reviewed studies published in prestigious journals around the world. To facilitate access to our scientific literature, … Continued

Formulary: Our new scientific formulas database

Through personalized medicine, doctors can prescribe specific dosages or combine treatments, and pharmacists can develop new potential solutions, whether via different administration routes as well as flavoring and packaging options. However, developing a new formulation involves some important steps and procedures to guarantee its quality. The preliminary step needed is to conduct a pre-formulation study … Continued

Addressing the specific needs of Pediatric and Geriatric patients through Oral Suspensions

Pediatric and geriatric patients require careful consideration when it comes to the administration of medication to ensure both safety and efficacy. Physiological characteristics of children and elderly differ considerably from that of adults; they may not be able to metabolize or eliminate active substances and excipients in pharmaceutical products in the same manner. Personalized medicine, … Continued

Build the Organization of the Future: Fagron’s Commitment to ESG and Stakeholder Engagement

Stakeholder engagement ESG (Environment, Social, and Governance) lies at the core of Fagron’s activities and strategy. Fagron products and services contribute every day to improving people’s health. As a global company with the purpose to create the future of personalizing medicine, we aim to produce all our products ethically and responsibly. We strive to create long-term value for … Continued